Corporate news releases play a pivotal role in keeping both existing shareholders and potential investors abreast of recent developments within publicly traded companies. This holds especially true in the vibrant OTC market, where numerous emerging companies offer a unique opportunity to invest in cutting-edge technologies at their inception.
With each passing week, these companies unveil crucial information that can often prove to be the turning point for their success or failure. Lets take a closer look at four stocks that have recently issued potentially noteworthy updates.
Epazz, Inc. (OTC: EPAZ), a dynamic force in the world of emerging OTC stocks, is making waves with its groundbreaking developments in drone technology, artificial intelligence software, cryptocurrency apps, blockchain mobile apps, and cloud-based business software solutions. EPAZ recently achieved a major milestone with the issuance of its third patent for the game-changing ZenaDrone 1000 Drone, equipped with cutting-edge AI Predictive capabilities.
This new patent not only solidifies Epazz's position as a key player in the rapidly evolving technology sector but also showcases the company's innovative approach to addressing critical industry challenges.
Epazz is strengthening its intellectual property and building a compelling portfolio of drone patents, poised to attract the attention of potential industry giants in the future, with the unique design of the ZenaDrone 1000 now protected by patent.
Epazz's decision to manufacture over 30 drones, including plans for Drone as a Service in Ireland and a joint venture with NightSun, LLC, shows a clear vision to meet the growing demand for drone technology across various markets.
Additionally, EPAZ's letter of support from the U.S. Air Force speaks volumes about the potential applications of ZenaDrone technology, particularly in the military domain. This endorsement opens doors to lucrative opportunities in the U.S. military sector, further strengthening Epazz's foothold in this competitive landscape.
Dr. Shaun Passley, CEO of Epazz, expressed unwavering confidence in the company's future, highlighting their dedication to delivering top-notch products to customers in Ireland and the U.S. The recent patent issuance cements Epazz's position as an innovative leader in the drone and AI industries, capturing the attention of savvy investors looking for promising OTC stocks.
Already lauded in sectors such as agriculture, oil and gas, wildfire prevention, and civil engineering, the ZenaDrone 1000's upcoming enhancements in AI capabilities are set to disrupt and redefine drone applications across industries.
Epazz's commitment to advancing its AI technology and utilizing predictive analytics positions EPAZ as a potential opportunity in the dynamic world of emerging Drone stocks.
The latest patent announcement exemplifies Epazz's pursuit of excellence and dedication to staying at the forefront of technology trends. As an emerging company, EPAZ could hold promise for investors looking to capitalize on innovative companies poised for success in the fast-paced and ever-changing tech landscape. With a vision for continued growth and a portfolio of groundbreaking solutions, EPAZ is an OTC penny stock to watch.
Therapeutic Solutions International, Inc. (OTC:TSOI) is a biotechnology company focused on developing immune modulation products for treating specific diseases. On July 31, TSOI released significant news that investors may want to take note of. TSOI announced they had secured a Notice Allowance from the US Patent Office. The notice of allowance covers a proprietary solution that the company's subsidiary, Campbell Neuroscience, is working on for preventing suicide.
The subsidiary has been working on a diagnostic approach designed to identify patients at risk of suicide. The unit leverages immunology-based assays to identify such patients. In its studies with various independent researchers, the company has successfully identified a specific type of neuroinflammation that contributes to suicidal thoughts and actions.
Campbell's Neuroscience approach stands out partly because it targets neuroinflammation and pathologically altered immunity in the brain. Campbell has already created numerous products in the race to come up with an effective diagnosis for suicidal tendencies.
The granting of a patent for a novel approach that helps reduce specific types of brain inflammation marks an essential milestone in the company's bid to address issues related to suicide cases. It also sets the company on a path to unlocking significant value in the sector.
The Notice of Allowance for a suicide prevention drug comes days after Therapeutic Solutions reiterated that its immune-oncology subsidiary, Res Nova Bio, had filed a patent for a new mechanism of action for breast cancer.
The new mechanism is for its immune therapy-enhancing product, FloraStilbene, a combination of pterostilbene and the abortion pill mifepristone. Initial trials have shown that the novel treatment under trial can potentially suppress the loss of T-cell activity due to growing breast cancer.
The treatment can enhance the survival chances of people with the deadly disease by suppressing T cell degradation. Patients with higher T cell receptors have always had a higher survival rate than patients with lower T cell levels.
DarkPulse, Inc. (OTC:DPLS) is a technology company that designs, develops, and distributes engineering installation and security systems. The company's joint venture unit, Neural Logistics, announced on August 1, 2023, that it has filed for a Humanitarian Use Device designation for a new prosthesis designed to restore speech to cognitively intact humans.
The new device, which uses the Neuronexus Neurotrophic Electrode (NXNE), results from decades of groundbreaking research and development. It consists of two parts, with the first implanted into the brain's speech motor cortex region and the second being the algorithm built to decode neural activity into speech.
Once approved, the Dark Pulse unit intends to offer it for use in treating ALS patients in the near future. The device promises to enhance the quality of life for ALS and locked-in patients who are unable to communicate even though they are cognitively intact. Securing the Humanitarian Use Device designation from the FDA would mark an important milestone in the push.
In March, the emerging company engaged the services of Keystone Global Holdings, a full-service construction and infrastructure firm, as it looked to unlock new growth opportunities. Dark Pulse is looking to leverage its partners' public and private relationships across the infrastructure and construction marketplace.
Keystone, which has extensive experience in providing various types of financial and strategic solutions, should also help Dark Pulse accelerate its growth plans. Part of the effort entails pursuing opportunities for growth in the infrastructure sector. Access to strategic capital should also allow the company to execute on the growing demand for its proprietary technologies and services from the government and various commercial customers.
SOHM, Inc. (OTC:SHMN) is a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs. On August 1, 2023, the company announced that it had signed a letter of intent to acquire stem cell disruptive technology and patents dubbed ABBIE.
The company is looking to acquire CGA Intellectual Holdings Inc. and its patented technology. Under the terms of the agreement, CGA is to provide cutting-edge stem cell regenerative and disruptive life sciences technology and other related strategies for the development of novel products and solutions.
The technology patents that SOHM is acquiring have already been approved in China and are pending approval in the US, the EU, Japan, and South Korea. According to Dry David Aguilar, who is the owner of the technology and patents, the binding-based integrating enzyme has the potential to circumvent the pain points often experienced with gene editing.
In addition, the ABBIE system will be utilized for human cell therapies and can also find great use in engineering plant DNA. Consequently, it could come in handy in enhancing the generation of biofuel. The system can also be sold as a kit for clients such as universities, pharmaceutical companies, and government laboratories. The ABBIE system is poised to enhance the SOHM footprint in the regenerative medicine market, valued at $20.04 billion as of 2021 and growing at a compound annual growth rate of 16.2%.
Meanwhile, SOHM closed financing on July 25, 2023, for its various ongoing and future projects. According to Chief Executive Officer Baron Night, they have secured funding for their San Diego Pharmaceutical plant for Phase 1 and Phase 2 development. Any remaining funds from the $5 million are to be used for future projects that should take the company to new levels.
The financing supports and aligns with the company's long-term growth strategy, which focuses on organic, inorganic, and vertical integration. SOHM is also committed to pursuing new opportunities aligned with its vision and goals.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.